Traditional Chinese medicine composition for treating recurrence of ovarian cancer

Through a composition containing traditional Chinese medicines such as Bupleurum, Scutellaria baicalensis, and Guizhi, it has achieved the effect of prolonging progression-free survival and reducing anxiety state in patients with biochemical relapse of ovarian cancer, and solved the lack of treatment methods for such patients in modern medicine. The problem of this problem provides a safe and effective alternative.

CN118903360APending Publication Date: 2024-11-08BEIJING CHINESE MEDICINE HOSPITAL AFFILIATED CAPITAL MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410999916.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing technology has limited treatment methods for biochemical recurrence of ovarian cancer, especially for asymptomatic biochemical recurrence patients. Modern medicine lacks effective treatment plans, which leads to patients who may miss the best treatment opportunity during the waiting period, and the side effects of traditional chemotherapy are greater. , affects the quality of life.

Method used

A Chinese medicine composition is adopted, including erectile dysfunction, scutellaria baicalensis, cinnamon twig, dried ginger, etc., erectile squid, squid, squid, and other medicines, cinnamon, chicken blood vine, and turtle worm, and other medicines. As a medicine, licorice is used to delay the clinical recurrence time and improve anxiety state by relieving liver and detoxifying, resolving phlegm and promoting blood circulation, and nourishing kidney yang.

Benefits of technology

This traditional Chinese medicine composition significantly prolongs progression-free survival in clinical applications, reduces the anxiety state of patients, provides a safe alternative treatment plan, delays the trend of clinical recurrence, and when modern medicine lacks effective means Shows advantages of long-term benefits.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ovarian cancer recurrence. The composition is prepared from radix bupleuri, scutellaria baicalensis, pinellia ternate, white peony root, rhizoma zingiberis, honey-fried licorice root, cassia twig, cinnamon, rhizoma coptidis from Sichuan of China, caulis spatholobi, ground beeltle, divaricate saposhnikovia root, nightshade, solanum lyratum, hedyotis diffusa and sculellaria barbata. The traditional Chinese medicine composition can improve the progression-free lifetime of ovarian cancer relapse patients and prolong clinical relapse; the traditional Chinese medicine composition has certain effects of soothing liver and relieving anxiety of patients. Under the condition that no optimal treatment means exists in modern medicine at present, the ovarian cancer recurrence prescription is an alternative scheme with certain advantages and good safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating recurrence of ovarian cancer. Background Art

[0002] Ovarian cancer is a common gynecological malignancy in clinical practice. Most patients have atypical early symptoms and are already in the advanced stage when diagnosed in hospital, with a poor prognosis (Temkin SM, Smeltzer MP, Dawkins MD, et al. Improving the quality of care for patients with advanced epithelial ovarian cancer: program components, implementation barriers, and recommendations [J]. Cancer, 2022, 128 (4): 654-664.). The morbidity of ovarian cancer ranks third among gynecological malignancies, and the mortality rate ranks first among gynecological tumors. This is related to the atypical early symptoms and lack of early diagnosis methods. It is difficult to completely remove the lesion during the first surgery, and the recurrence rate is as high as 50% to 70% (Morand S, Devanaboyina M, Staats H, et al. Ovarian cancer immunotherapy and personalized medicine [J]. Int J Mol Sci, 2021, 22 (12): 6532-6535.). Most patients with recurrent ovarian cancer have already progressed to the advanced stage and are incurable, with a poor prognosis. Studies have shown that 80% of patients with recurrent ovarian cancer have elevated CA125 (SALANI R, BACKES FJ, FUNG MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations [J]. Am J Obstet Gynecol, 2011, 204 (6): 466-478.).The study by RUSTIN et al. included 1442 EOC patients who achieved complete remission after the first treatment. During the follow-up, 529 patients (nearly 1 / 3) experienced a stage in which CA125 increased to 2 times the upper limit of normal value but there was no evidence of clinical recurrence (RUSTING J, VAN DER BURG ME, GRIFFIN CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05 / EORTC 55955): arandomised trial [J]. Lancet, 2010, 376 (9747): 1155-1163.). In combination with clinical practice, referring to the definition of biochemical recurrence of prostate cancer (SMITS M, MEHRA N, SEDELAAR M, et al. Molecular biomarkers to guide precision medicine in localized prostate cancer [J]. Expert Rev Mol Diagn, 2017, 17 (8): 791-804.), some scholars call cases with elevated tumor markers after ovarian cancer treatment but no imaging evidence "biochemical recurrence of ovarian cancer" (KRISTELEIT R, DAVIDENKO I, SHIRINKIN V, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer [J]. Gynecol Oncol, 2017, 146 (3): 484-490.). "Asymptomatic" is the prerequisite for diagnosing biochemical recurrence. Modern medicine has limited treatment options for biochemical recurrence of ovarian cancer. The NCCN guidelines recommend treatment options including watchful waiting, chemotherapy, or participation in clinical trials. Watchful waiting is the first choice, but this "wait-and-see" approach does not specify a clear waiting time. During the waiting process, patients may suffer from excessive thinking, excessive psychological pressure, and subsequent non-specific symptoms, which is not conducive to improving the quality of life and may miss the best time for treatment. The treatment regimen based on paclitaxel combined with platinum chemotherapy drugs has not achieved significant long-term survival benefits, and the quality of life has been significantly reduced due to side effects.Data from a European multicenter clinical trial suggested that immediate chemotherapy for relapsed patients (based on CA125 levels detected in asymptomatic patients) failed to improve survival outcomes (Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer: a randomised trial [J]. Lancet 2010, 376 (9747): 1155.).

[0003] In the process of clinical treatment, pulse diagnosis and acupuncture combined with Chinese herbal medicine can increase and prolong the efficacy. From the perspective of TCM pathogenesis and syndrome differentiation, the onset of ovarian cancer is a process of alternating positive and negative forces, and imbalance of qi and blood. Professor Yu Yun believes that for patients with biochemical recurrent ovarian cancer, after surgery and postoperative chemotherapy, qi and blood are damaged, and the pattern of positive deficiency and evil is formed. The spleen and stomach function is impaired, the spleen is weak and the water and dampness are disordered, and the dampness is endogenous; the qi and blood are damaged and the circulation is not smooth, and blood stasis is formed. In the process of clinical treatment, spleen and kidney deficiency and dampness and blood stasis are common. Treatment can be selected by syndrome differentiation, including Sijunzi Decoction, Xiangsha Liujunzi Decoction, Shenling Baizhu San, and Lizhong Decoction (Chen Xiaofeng, Xiao Jing, Yu Yun. Yu Yun's experience in pulse diagnosis and acupuncture combined with acupuncture and medicine for biochemical recurrent ovarian cancer [J]. Shizhen Chinese Medicine, 2019, 30(02): 474-476.). Summary of the invention

[0004] The purpose of the present invention is to provide a treatment plan of traditional Chinese medicine for biochemical recurrence of ovarian cancer, that is, to mainly treat Shaoyang, supplemented by large doses of detoxifying and anti-cancer Chinese medicine to attack toxins and eliminate heat. The Chinese medicine composition has the effect of delaying the appearance of clinical recurrence time, and has a certain effect of soothing the liver and reconciling and improving the patient's anxiety state. In the case that modern medicine currently has no optimal treatment method, it is an alternative plan with certain advantages and good safety.

[0005] In a first aspect, the present invention provides a Chinese medicine composition for treating recurrence of ovarian cancer, wherein the Chinese medicine composition is prepared from the following Chinese medicines in parts by weight:

[0006] The main medicine includes 5-20 parts of bupleurum, 5-20 parts of scutellaria, 5-20 parts of cinnamon twig and 5-20 parts of dried ginger;

[0007] The adjuvant drugs include 20-45 parts of peony root, 5-20 parts of siler, 20-45 parts of nightshade, 20-45 parts of white safflower, 40-80 parts of oldenlandia diffusa and 40-80 parts of barbata;

[0008] The adjuvants include 5-15 parts of cinnamon bark, 10-25 parts of rhizoma corydalis, 10-25 parts of rhizoma pinelliae, 20-45 parts of reticulatae spatholobi and 5-20 parts of ground beetle;

[0009] The adjuvant drug is 5-20 portions of roasted licorice root.

[0010] Preferably, the Chinese medicine composition for treating recurrence of ovarian cancer is prepared from the following Chinese medicines in parts by weight:

[0011] The main medicine includes 5-15 parts of bupleurum, 5-15 parts of scutellaria, 5-15 parts of cinnamon twig and 5-15 parts of dried ginger;

[0012] The adjuvant drugs include 20-40 parts of peony root, 5-15 parts of siler, 20-40 parts of nightshade, 20-40 parts of white peony root, 40-70 parts of oldenlandia diffusa and 40-70 parts of barbata;

[0013] The adjuvants include 5-12 parts of cinnamon bark, 10-20 parts of rhizoma corydalis, 10-20 parts of rhizoma pinelliae, 20-40 parts of millettia reticulata and 5-15 parts of ground beetle;

[0014] The adjuvant drug is 5-15 parts of roasted licorice root.

[0015] Preferably, the Chinese medicine composition for treating recurrence of ovarian cancer is prepared from the following Chinese medicines in parts by weight:

[0016] The main medicine includes 5-10 parts of bupleurum, 5-10 parts of scutellaria, 5-10 parts of cinnamon twig and 5-10 parts of dried ginger;

[0017] The adjuvant drugs include 20-35 parts of peony root, 5-10 parts of siler, 20-35 parts of nightshade, 20-35 parts of white safflower, 40-60 parts of oldenlandia diffusa and 40-60 parts of barbata;

[0018] The adjuvants include 5-8 parts of cinnamon bark, 10-15 parts of rhizoma corydalis, 10-15 parts of rhizoma pinelliae, 20-35 parts of reticulatae spatholobi and 5-10 parts of ground beetle;

[0019] The adjuvant is 5-10 portions of roasted licorice root.

[0020] Furthermore, the ovarian cancer recurrence includes biochemical recurrence and clinical recurrence.

[0021] Preferably, the ovarian cancer recurrence refers to biochemical recurrence.

[0022] In a second aspect, the present invention provides a Chinese medicine preparation made from the Chinese medicine composition described in the first aspect, wherein the Chinese medicine preparation comprises pharmaceutically acceptable excipients required for the corresponding preparation.

[0023] Furthermore, the excipient is a pharmaceutical excipient that enhances the efficacy, reduces toxicity and / or alleviates side effects of the main drug.

[0024] Furthermore, the Chinese medicine preparation is one or more of paste prescriptions, pills, pills, decoctions, granules, capsules, powders and / or tablets.

[0025] In a third aspect, the present invention provides use of the Chinese medicine composition described in the first aspect or the Chinese medicine preparation described in the second aspect in the preparation of a drug for treating biochemical recurrence of ovarian cancer.

[0026] Furthermore, the ovarian cancer recurrence includes biochemical recurrence and clinical recurrence.

[0027] Preferably, the ovarian cancer recurrence refers to biochemical recurrence.

[0028] The medicinal properties and effects of each Chinese medicinal material in the present invention are as follows:

[0029] Bupleurum: Spicy and bitter in taste, slightly cold in nature. Enters the liver, gallbladder, and lung meridians. Has the effects of dispersing fever, relieving liver depression, and raising Yang Qi. Used for colds and fever, alternating cold and heat, chest and flank pain, irregular menstruation, uterine prolapse, and rectal prolapse.

[0030] Scutellaria baicalensis: bitter in taste, cold in nature. Enters the lung, gallbladder, spleen, large intestine, and small intestine meridians. It has the effects of clearing away heat and dampness, purging fire and detoxifying, stopping bleeding, and calming the fetus. It is used for damp-heat, summer dampness, chest tightness and nausea, damp-heat fullness, diarrhea, jaundice, lung heat cough, high fever and thirst, blood heat vomiting and bleeding, carbuncle, sore, and fetal movement disorder.

[0031] Pinellia tuber: pungent, warm in nature; toxic. Enters the spleen, stomach, and lung meridians. Has the effects of drying dampness and resolving phlegm, relieving adverse reactions and stopping vomiting, and dissolving lumps and knots. Used for damp phlegm and cold phlegm, cough, asthma, excessive phlegm, phlegm and fluid, dizziness and palpitations, dizziness due to wind phlegm, phlegm and syncope, headache, vomiting and nausea, chest and abdominal distension, plum pit qi; external treatment of carbuncle, swelling, and phlegm nodules.

[0032] Hang Shao: bitter, sour, slightly cold. Enters the liver meridian and spleen meridian. Has the effects of nourishing blood and softening the liver, relieving pain, and consolidating yin and relieving sweat. Used for chest, abdomen, flank pain, diarrhea, abdominal pain, spontaneous sweating, night sweats, yin deficiency fever, irregular menstruation, metrorrhagia, and leucorrhea.

[0033] Dried ginger: spicy, hot. Enters the spleen, stomach, kidney, heart, and lung meridians. It has the effects of warming the middle and dispelling cold, restoring yang and unblocking meridians, warming the lungs and transforming fluid. It is used for cold pain in the abdomen, vomiting and diarrhea, cold limbs and weak pulse, asthma and cough due to cold fluid.

[0034] Roasted Licorice: Sweet in taste, neutral in nature. Enters the heart, lung, spleen, and stomach meridians. Has the effects of tonifying the spleen and stomach, replenishing qi and restoring pulse. Used for spleen and stomach weakness, fatigue, palpitations, and irregular pulse.

[0035] Cinnamon twig: pungent, sweet, warm in nature. Enters the heart, lung, and bladder meridians. Has the effects of sweating, relieving muscles, warming and unblocking meridians, assisting yang and transforming qi, and calming and descending qi. Used for colds, cold pain in the abdomen, amenorrhea due to cold blood, joint pain, phlegm and fluid retention, edema, palpitations, and running pig.

[0036] Cinnamon: pungent, sweet, very hot. Enters the kidney, spleen, heart, and liver meridians. It has the effects of replenishing fire and yang, guiding fire back to the origin, dispersing cold and relieving pain, and warming and unblocking the meridians. It is used for impotence, cold uterus, cold pain in the waist and knees, asthma due to kidney deficiency, floating of false yang, dizziness and red eyes, cold pain in the heart and abdomen, vomiting and diarrhea due to deficiency and cold, abdominal pain due to cold hernia, dysmenorrhea and amenorrhea.

[0037] Chuanlian: bitter, cold in nature. Enters the heart, liver, stomach meridians; large intestine meridian. Has the effects of purging fire, drying dampness, detoxifying, and killing insects. Used for seasonal heat toxins, typhoid fever, excessive heat and restlessness, fullness and vomiting, bacillary dysentery, hot diarrhea and abdominal pain, lung congestion, vomiting, epistaxis, bleeding, thirst, malnutrition, ascariasis, whooping cough, sore throat, conjunctivitis, mouth sores, carbuncle sores, eczema, and burns caused by hot water or fire.

[0038] Millettia reticulata: bitter, sweet, warm in nature. Enters the liver and kidney meridians. Has the effects of promoting blood circulation, tonifying blood, regulating menstruation and relieving pain, relaxing tendons and activating collaterals. Used for irregular menstruation, dysmenorrhea, amenorrhea, rheumatic arthralgia, numbness and paralysis, and blood deficiency and chlorosis.

[0039] Earthworm: salty, cold in nature; slightly toxic. Enters the liver meridian. Has the effects of breaking blood and removing blood stasis, and healing tendons and bones. Used for traumatic injuries, tendon injuries and fractures, blood stasis and amenorrhea, abdominal pain due to postpartum blood stasis, and lumps.

[0040] Saposhnikovia root: Spicy, sweet, slightly warm in nature. Enters the bladder, liver, and spleen meridians. Has the effects of dispelling wind and relieving exterior symptoms, relieving dampness and relieving pain, and stopping spasms. Used for colds and headaches, rheumatic pain, urticaria itching, and tetanus.

[0041] Solanum nigrum: bitter, cold in nature. It has the effects of clearing away heat and detoxifying, promoting blood circulation and reducing swelling. It is used for furuncle, carbuncle, erysipelas, sprains, chronic tracheitis, acute nephritis, skin eczema, dysuria, excessive leucorrhea, prostatitis, and dysentery.

[0042] Sophora flavescens: bitter, slightly cold. Slightly toxic. Enters the liver and stomach meridians. Has the effects of clearing away heat, promoting dampness, dispelling wind, and detoxifying. Used for malaria, jaundice, edema, gonorrhea, rheumatic joint pain, erysipelas, and furuncle.

[0043] Herba Ophiopogonis: bitter and sweet, cold in nature. Enters the heart, liver, and spleen meridians. Has the effects of clearing heat, promoting dampness, and detoxifying. Used for lung heat, cough, tonsillitis, pharyngitis, appendicitis, dysentery, urinary tract infection, jaundice, hepatitis, pelvic inflammatory disease, adnexitis, carbuncle, furuncle, snake bites, and tumors. Can also be used for digestive tract cancer.

[0044] Scutellaria barbata: pungent, bitter, cold in nature. Enters the lung, liver, and kidney meridians. Has the effects of clearing away heat and detoxifying, removing blood stasis and promoting diuresis. Used for carbuncle, sore throat, injuries from falls, edema, jaundice, snake and insect bites.

[0045] The treatment principle of the present invention is:

[0046] This prescription is modified based on Chaihu Guizhi Ganjiang Decoction, with the purpose of harmonizing Shaoyang and dredging the key organs. It is used to treat ovarian cancer in the biochemical recurrence stage (tumor markers are elevated, and no lesions are found in imaging examinations), when the cancer is latent and ready to break out. At this time, according to the Six Meridians Syndrome Differentiation, the disease is in Shaoyang, which is half-exterior and half-interior. The treatment is mainly to regulate and benefit Shaoyang, supplemented by large doses of detoxifying and anti-cancer Chinese medicine to attack the toxin and eliminate the heat.

[0047] In the Chinese medicine composition of the present invention, bupleurum, scutellaria, cinnamon twig and dried ginger are the main drugs, and the main components of bupleurum cinnamon twig and dried ginger soup are taken, which has the function of reconciling Shaoyang and dredging the pivot. With peony root, fangfeng, nightshade, white peony root, herba schizonepetae and Scutellaria barbata as the ministers, peony root softens the liver, fangfeng dispels wind and calms the wood, and strengthens the effect of the monarch drug on regulating the liver and calming the wood; nightshade, white peony root, herba schizonepetae and Scutellaria barbata all have the effect of clearing heat and detoxifying, and the large group of detoxifying drugs are used in super conventional doses, and the effect of clearing heat and detoxifying is doubled to treat the "burning" heat of cancer poison. With pinellia, millet vine, earthworm, cinnamon and coptis as the ministers, tumors are often combined with phlegm and blood stasis, pinellia root dissipates phlegm and disperses knots, millet vine and earthworm promote blood circulation and remove blood stasis, which is intended to dissipate phlegm and promote blood circulation. The heart and kidney are the mother and child of liver wood, and cinnamon and coptis barbata are the two medicines that communicate the heart and kidney, clear heart fire, warm kidney water, and replenish the mother and purge the child. Roasted licorice is used as a messenger to balance the harsh properties of various medicines.

[0048] Beneficial Effects

[0049] The progression-free survival of patients with biochemical recurrence of ovarian cancer who took the biochemical recurrence prescription for ovarian cancer in the present invention exceeded the mean value reported in the research, showing a certain trend of prolonging clinical recurrence and having the advantage of long-term benefit; and the biochemical recurrence prescription for ovarian cancer of the present invention has a certain effect of soothing the liver and reconciling and improving the anxiety state of patients, and the SAS score of patients decreased significantly in the eighth week of treatment; in the case that modern medicine currently has no optimal treatment method, the biochemical recurrence prescription for ovarian cancer is an alternative with certain advantages and good safety. DETAILED DESCRIPTION

[0050] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0051] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0052] Explanation of terms

[0053] The GCIG standard of the Global Gynecologic Oncology Group divides ovarian cancer recurrence into clinical recurrence and biochemical recurrence. The former refers to the presence of clear recurrence metastases or clinical symptoms on imaging (CT or MRI, etc.), and the latter refers to the absence of clear recurrence metastases and clinically related symptoms, but the ovarian cancer tumor marker CA125 continues to increase, exceeding the normal value of CA125 or twice or more of the upper limit of the previous lowest value of CA125.

[0054] Example 1 Chinese medicine composition

[0055] 1. Prescription for biochemical recurrence of ovarian cancer: 10g of Bupleurum, 10g of Scutellaria, 15g of Pinellia, 30g of Paeonia lactiflora, 10g of Dry Ginger, 10g of Roasted Licorice, 10g of Cinnamon Twig, 8g of Cinnamon Bark, 15g of Coptis chinensis, 30g of Millettia reticulata, 10g of Eupolyphaga sinensis, 10g of Saposhnikovia diffusa, 30g of Solanum nigrum, 30g of Bletilla striata, 60g of Hedyotis diffusa, and 60g of Scutellaria barbata.

[0056] Preparation method: Put the above medicinal materials into a boiling pot, add 8 times the amount of water and soak for 30 minutes, decoct for 25 minutes for the first time, and add 6 times the amount of water and decoct for 25 minutes for the second time. The combined medicinal liquid is concentrated and filtered to 400 ml.

[0057] Example 2 Clinical Study

[0058] 1. Research Methods

[0059] This study adopted a single-arm clinical study with its own before-after control.

[0060] 2. Research subjects:

[0061] 2.1 Case source:

[0062] Patients with biochemical recurrence of ovarian cancer were from the Department of Oncology, Beijing Hospital of Traditional Chinese Medicine. The time span was from July 2021 to January 2024, with a total of 28 patients enrolled.

[0063] 2.2 Diagnostic criteria:

[0064] 2.2.1 Western medicine diagnostic criteria:

[0065] The pathological diagnosis of epithelial ovarian cancer was clear. The patient received cytoreductive surgery and adequate courses of adjuvant chemotherapy as initial treatment, achieving complete clinical remission. Elevated CA125 levels were found during routine follow-up examinations, but no local lesions or distant metastases were found by imaging examinations (such as CT or MRI).

[0066] According to the GCIG criteria, an increase in CA125 requires one of the following criteria to be met:

[0067] ① CA125 was elevated before initial treatment and returned to normal after treatment. CA125 was ≥ 2 times the upper limit of normal value in two random tests (with an interval of more than 1 week).

[0068] ② CA125 was elevated before initial treatment and did not return to normal after treatment. In two random tests, CA125 was ≥ 2 times the previous lowest value (with an interval of more than 1 week).

[0069] ③ Before initial treatment, CA125 was within the reference range, and in two random tests, CA125 was ≥ 2 times the upper limit of normal value (with an interval of more than 1 week).

[0070] 2.2.2 TCM diagnostic criteria:

[0071] Because these patients mostly do not have clinical symptoms and are in an unidentifiable state, this study adopted the method of disease differentiation and treatment, and as long as they met the biochemical recurrence of ovarian cancer, they could be included.

[0072] 2.3 Inclusion and Exclusion Criteria:

[0073] 2.3.1 Inclusion criteria:

[0074] (1) Meet the diagnosis of epithelial ovarian cancer;

[0075] (2) CA125 elevation meets GCIG criteria;

[0076] (3) serum CA125 does not exceed 10 times the upper limit of normal value;

[0077] (4) More than 1 month had passed since the last chemotherapy or other anti-tumor Western medicine treatment;

[0078] (5) KPS greater than or equal to 60 points;

[0079] (6) Age 25-75 years old;

[0080] 2.3.2 Exclusion criteria:

[0081] (1) The presence of recurrence or metastasis on imaging, including unexplained pleural effusion or intestinal obstruction;

[0082] (2) Currently receiving or planning to receive anti-tumor Western medicine treatment, such as chemotherapy, targeted therapy, etc.;

[0083] (3) Other diseases that may cause elevated serum CA125, including benign gynecological tumors, inflammatory diseases, endometriosis, etc.;

[0084] (4) Patients with severe liver and kidney dysfunction.

[0085] 2.4 Falling off and rejection criteria:

[0086] 2.4.1 Case exclusion and dropout

[0087] (1) If a case is found not to meet the inclusion criteria after inclusion, it must be excluded;

[0088] (2) Subjects with poor compliance, serious adverse events, and other reasons that make them unsuitable to continue the trial, or those who withdraw on their own initiative are all considered dropouts.

[0089] 2.4.2 Treatment of dropout cases

[0090] When a subject drops out, the researcher should take active measures to complete the last test as much as possible in order to analyze its efficacy and safety. For all dropout cases, the trial conclusion form and the reason for the dropout should be filled in the case report form.

[0091] 3. Treatment methods:

[0092] The prescription of the present invention (prescription for biochemical recurrence of ovarian cancer): 10g of bupleurum, 10g of scutellaria, 15g of pinellia, 30g of peony root, 10g of dried ginger, 10g of roasted liquorice, 10g of cassia twig, 8g of cinnamon bark, 15g of chuanxiong, 30g of millettia reticulata, 10g of earthworm, 10g of siler, 30g of solanum nigrum, 30g of white peony root, 60g of oldenlandia diffusa, and 60g of Scutellaria barbata.

[0093] Usage: decoct in water and drink warm, one dose per day, divided into 2 doses, 200 ml each time.

[0094] Treatment course: Continuous use until tumor progression, patients taking 56 doses will be included in the per-protocol analysis set.

[0095] Regulations on combined medication: Subjects cannot use Western anti-tumor drugs during the study, including targeted therapy, immunotherapy (PD-1, PD-L1), chemotherapy, radiotherapy, etc.

[0096] 4. Observation indicators

[0097] 4.1 Main indicators:

[0098] Progression-free survival (PFS): refers to the time from the enrollment of patients to the occurrence of radiographic recurrence of the tumor, with imaging review (abdominal and pelvic CT / ultrasound) every 8 weeks.

[0099] 4.2 Secondary indicators:

[0100] ① Serum tumor marker CA125: Compare the changes of tumor markers before and after treatment, and review every 4 weeks.

[0101] ②CA125 response rate: A decrease of at least 50% in CA125 was considered a response. The response rates at weeks 4 and 8 were calculated with reference to the GCIG standard.

[0102] ③ Self-Rating Anxiety Scale (SAS): calculate the SAS scores at the 4th and 8th weeks.

[0103] ④Safety indicators: Record the adverse reactions of the patient during medication, regularly check blood routine, urine routine, stool routine, liver and kidney function, etc., and review every 4 weeks during medication.

[0104] 5. Efficacy evaluation

[0105] The main observation indicator of this study was progression-free survival. Since the single-arm trial lacked a control group, the reference literature reported that the average time from the increase of tumor markers to clinical recurrence in patients with biochemical recurrence of ovarian cancer was 2-6 months (Chen Huizhen. Gynecological Oncology [M]. Wuhan: Hubei Science and Technology Press, 2011: 841.). This study used 6 months as the cutoff point to conduct a horizontal comparison of clinical efficacy.

[0106] 6. Research Results

[0107] 6.1 Case data

[0108] All case data were derived from 28 patients who met the inclusion and exclusion criteria and visited the Department of Oncology at Beijing Hospital of Traditional Chinese Medicine from July 2021 to January 2024.

[0109] 6.2 Baseline information

[0110] A total of 30 patients were enrolled, 2 of whom dropped out, leaving 28 patients. All of them were patients with epithelial ovarian cancer, with an average age of (66.07±7.71) years, an average time from the end of surgery of (29.35±3.02) weeks, and an average medication time of (11.39±3.602) weeks (median follow-up time).

[0111] 6.3 Evaluation of efficacy

[0112] Progression-free survival: It conforms to the normal distribution, with the calculated mean and standard deviation of (22.50±8.50) weeks, which is longer than the average recurrence time of 4-6 months reported in the study.

[0113] CA125 value changes and response rate: At baseline, 4 weeks and 8 weeks, the mean and standard deviation of CA125 were 85.30±39.41, 68.93±36.57 and 85.30±39.41, of which the difference between the 4th week and the baseline was statistically significant (P=0.002), while the difference between the 8th week and the baseline was not statistically significant (P=0.736). The response rate was 14.3% in the 4th week and 35.7% in the 8th week.

[0114] Self-Rating Anxiety Scale (SAS): At baseline, 4 weeks, and 8 weeks, the mean and standard deviation of SAS were 50.86±16.73, 45.05±17.51, and 40.41±16.11, respectively. There was no significant difference between the baseline and the 4th week (P=0.060), but a certain trend of benefit was shown. There was a significant difference between the baseline and the 8th week (P=0.008).

[0115] Safety evaluation: During the long-term follow-up and treatment, all patients did not experience obvious discomfort and serious adverse events, and no obvious abnormalities were found in the patients' blood, urine routine, liver and kidney functions.

[0116] 7. Conclusion

[0117] The progression-free survival of patients who took the ovarian cancer biochemical recurrence prescription in the present invention exceeded the mean value reported in the study, and the SAS score of patients with ovarian cancer biochemical recurrence decreased significantly in the eighth week of treatment. This shows that the prescription of the present invention has a certain tendency to prolong clinical recurrence and has the advantage of long-term benefits; and the prescription of the present invention also has a certain advantage of reducing the risk of anxiety in patients and has good safety during the treatment process. However, the biochemical recurrence prescription did not show a significant advantage in reducing the tumor marker CA125 in this study.

[0118] Typical clinical cases

[0119] Case 1

[0120] Patient: Zhao

[0121] Age: 59

[0122] First visit: October 22, 2021

[0123] Chief complaint:

[0124] One year and three months after ovarian cancer surgery, CA125 increased for 6 months.

[0125] History of present illness:

[0126] On July 3, 2020, the patient had irregular vaginal bleeding, and abdominal ultrasound showed solid masses on both ovaries. She underwent "bilateral ovarian + total hysterectomy" at a local hospital. Postoperative pathology showed high-grade ovarian serous carcinoma, FIGO stage: stage II, lymph node metastasis: none, distant metastasis: none, no radiotherapy, chemotherapy or target-free treatment was performed after surgery, and no obvious abnormalities were found in regular follow-up examinations. In April 2021, CA125 increased by 75.12U / ml, and abdominal and pelvic enhanced CT showed no obvious abnormalities. On October 6, 2021, CA125 increased by 93.46U / ml.

[0127] Immediate symptoms:

[0128] Anxiety, insomnia, good appetite, regular bowel movements, pale red tongue, thin white fur, and wiry pulse.

[0129] Past history:

[0130] History of hypertension for 2 years.

[0131] Auxiliary examination:

[0132] On October 6, 2021, CA125 of the Affiliated Hospital of Inner Mongolia University for Nationalities increased by 93.46U / ml, and pelvic CT: after bilateral ovarian and uterine surgery, no obvious mass was found, and there was a small amount of fluid in the pelvis.

[0133] diagnosis:

[0134] Traditional Chinese Medicine: Ovarian cancer, liver depression and toxicity syndrome;

[0135] Western medicine: Ovarian high-grade serous carcinoma, FIGO stage II after surgery.

[0136] Governing Law:

[0137] Regulate Liver Pingmu, Detoxify and Anti-cancer

[0138] prescription:

[0139] Bupleurum 10g, Scutellaria 10g, Pinellia 15g, Paeonia lactiflora 30g, Dry ginger 10g, Roasted Licorice 10g, Cinnamon twig 10g, Cinnamon bark 8g, Coptis chinensis 15g, Millettia reticulata 30g, Eupolyphaga sinensis 10g, Saposhnikovia diffusa 10g, Solanum nigrum 30g, Bletilla striata 30g, Hedyotis diffusa 30g, Scutellaria barbata 30g. Usage: decoct in water and take warm, one set per day, divided into 2 doses, 200ml each time, 28 sets for the first visit, no special discomfort was reported afterwards, Hedyotis diffusa and Scutellaria barbata were increased to 60g, a total of 84 sets were taken, and then the medication was stopped on its own.

[0140] Treatment Effect:

[0141] The CA125 level rechecked on November 27, 2021 was 91.9U / ml, the CA125 level rechecked on December 22, 2021 was 99.1U / ml, the CA125 level rechecked on January 22, 2021 was 127.4U / ml, and the transvaginal gynecological ultrasound level rechecked on April 21, 2022 showed a mixed mass in the left adnexal area (approximately 3.0×2.4cm in size) and a small amount of pelvic effusion, which was considered to be a clinical recurrence, with a PFS of 6 months.

[0142] Case 2

[0143] Patient: Xing

[0144] Age: 75

[0145] First visit: December 13, 2021

[0146] Chief complaint:

[0147] CA125 increased for 2 months 9 months after ovarian cancer surgery.

[0148] History of present illness:

[0149] In March 2020, a pelvic mass was found during a physical examination (the specific description is unclear), and "bilateral ovarian + total hysterectomy" was performed. Postoperative pathology showed ovarian serous carcinoma, FIGO stage: IIIC, and 6 cycles of paclitaxel combined with carboplatin chemotherapy were performed after surgery. In September 2021, CA125 increased by 63.25U / ml, and no obvious abnormalities were found in the abdominal and pelvic enhanced CT. On December 3, 2021, CA125 increased by 164.5U / ml.

[0150] Immediate symptoms:

[0151] Fatigue, spontaneous sweating, poor appetite, difficulty sleeping, normal urination, pale red tongue, thin yellow tongue coating with teeth marks on the edges, and wiry pulse.

[0152] Past history:

[0153] History of hypertension for 10 years.

[0154] Auxiliary examination:

[0155] 2021-9-29 Gynecological Ultrasound of Mudanjiang Cancer Hospital: After total hysterectomy, no obvious abnormalities were found in the pelvic cavity, and no obvious enlarged lymph nodes were found in the bilateral inguinal areas.

[0156] diagnosis:

[0157] Traditional Chinese Medicine: Ovarian cancer, liver depression, spleen deficiency, toxicity syndrome;

[0158] Western medicine: FIGO stage IIIC ovarian hyperserous cancer after surgery.

[0159] Governing Law:

[0160] Regulate Liver Pingmu, Detoxify and Anti-cancer

[0161] prescription:

[0162] Bupleurum 10g, Scutellaria 10g, Pinellia 15g, Paeonia lactiflora 30g, Dry ginger 10g, Roasted Licorice 10g, Cinnamon twig 10g, Cinnamon bark 8g, Coptis chinensis 15g, Millettia reticulata 30g, Eupolyphaga sinensis 10g, Saposhnikovia diffusa 10g, Solanum nigrum 30g, Bletilla striata 30g, Hedyotis diffusa 60g, Scutellaria barbata 60g. Usage: Decoction in water and take warm, one set per day, divided into 2 doses, 200ml each time, a total of 56 sets were taken. Later, due to the COVID-19 pandemic, he did not continue to come to our hospital for follow-up and prescription adjustment.

[0163] Treatment Effect:

[0164] The CA125 level on January 3, 2022 was 90U / ml, the CA125 level on February 8, 2022 was 113U / ml, the CA125 level on June 10, 2022 was 106.5U / ml, and the abdominal CT level on May 30, 2022 showed: the intrahepatic low-density nodule was approximately 2 cm in diameter, which was considered to be a clinical recurrence, and the PFS was 6 months.

[0165] Case 3

[0166] Patient: Wang

[0167] Age: 75

[0168] First visit date: October 8, 2021

[0169] Chief complaint:

[0170] One year and one month after ovarian cancer surgery, CA125 increased for one month.

[0171] History of present illness:

[0172] In August 2020, due to abdominal distension, ultrasound showed solid mass in the right adnexa and pelvic cavity. On September 4, 2020, laparoscopic "bilateral ovarian + total hysterectomy" was performed. Postoperative pathology showed high-grade ovarian serous carcinoma, retroperitoneal lymph node metastasis, FIGO stage: stage III, homologous recombination defect HRD genomic instability score: positive (91 points), BRCA mutation status negative, PD-L1 expression test results: TPS24%, CPS 38, tumor cell ratio 30%, with infiltrating immune cells. After surgery, 6 cycles of paclitaxel + carboplatin + bevacizumab treatment were performed, followed by bevacizumab treatment. On September 27, 2021, CA125 was increased by 67.32U / ml, and enhanced CT of the abdomen and pelvis showed that there was a soft tissue nodule with a diameter of about 1.2cm in the pelvic cavity. It is recommended to continue regular review. On November 17, 2021, CA125 was increased by 79.39U / ml.

[0173] Immediate symptoms:

[0174] Fatigue, good appetite, poor sleep, normal bowel movements, occasional dull pain in the abdomen, pale red tongue, thin white fur with teeth marks on the edges, and thready pulse. Past medical history:

[0175] He has a 12-year history of diabetes and an 8-year history of coronary heart disease.

[0176] Auxiliary examination:

[0177] (Pelvic CT on September 29, 2021): After bilateral adnexectomy and hysterectomy, a soft tissue nodule with a diameter of about 1.2 cm and uneven density was found on the right posterior wall of the bladder.

[0178] diagnosis:

[0179] Traditional Chinese Medicine: Ovarian cancer, liver depression, spleen deficiency, toxicity syndrome;

[0180] Western medicine: FIGO stage III after surgery for ovarian hyperserous carcinoma.

[0181] Governing Law:

[0182] Regulate Liver Pingmu, Detoxify and Fight Cancer

[0183] prescription:

[0184] 10g of Bupleurum, 10g of Scutellaria, 15g of Pinellia, 30g of Paeonia lactiflora, 10g of Dry Ginger, 10g of Roasted Licorice, 10g of Cinnamon Twig, 8g of Cinnamon Bark, 15g of Coptis chinensis, 30g of Millettia reticulata, 10g of Eupolyphaga, 10g of Saposhnikovia diffusa, 30g of Solanum nigrum, 30g of Bletilla striata, 90g of Hedyotis diffusa, 90g of Scutellaria barbata. Usage: decoct in water and take warm, one set a day, divided into 2 times, 200ml each time, a total of 28 sets, abdominal distension after taking the medicine, 4-5 bowel movements a day, unformed, no watery or mucous bloody stools, then reduce Hedyotis diffusa and Scutellaria barbata to 60g, bowel movements return to normal, 1-2 times a day, abdominal distension is relieved, take 56 sets continuously after adjusting the prescription.

[0185] Treatment Effect:

[0186] On October 28, 2021, CA125 was 54.0U / ml, on November 17, 2021, CA125 was 61.8U / ml, on December 27, 2021, CA125 was 144.3U / ml, and on March 25, 2022, pelvic CT was performed: metastatic tumors around the hernia orifice of the lower abdomen and multiple pelvic lymph node metastases. PFS is 5 months.

Claims

1. A Chinese medicine composition for treating recurrence of ovarian cancer, the Chinese medicine composition being prepared from the following Chinese medicines in parts by weight: The main medicine includes 5-20 parts of bupleurum, 5-20 parts of scutellaria, 5-20 parts of cinnamon twig and 5-20 parts of dried ginger; The adjuvant drugs include 20-45 parts of peony root, 5-20 parts of siler, 20-45 parts of nightshade, 20-45 parts of white safflower, 40-80 parts of oldenlandia diffusa and 40-80 parts of barbata; The adjuvants include 5-15 parts of cinnamon bark, 10-25 parts of rhizoma corydalis, 10-25 parts of rhizoma pinelliae, 20-45 parts of reticulatae spatholobi and 5-20 parts of ground beetle; The adjuvant drug is 5-20 portions of roasted licorice root.

2. The Chinese medicine composition for treating recurrent ovarian cancer according to claim 1, wherein the Chinese medicine composition is made of the following Chinese medicines in parts by weight: The main medicine includes 5-15 parts of bupleurum, 5-15 parts of scutellaria, 5-15 parts of cinnamon twig and 5-15 parts of dried ginger; The adjuvant drugs include 20-40 parts of peony root, 5-15 parts of siler, 20-40 parts of nightshade, 20-40 parts of white peony root, 40-70 parts of oldenlandia diffusa and 40-70 parts of barbata; The adjuvants include 5-12 parts of cinnamon bark, 10-20 parts of rhizoma corydalis, 10-20 parts of rhizoma pinelliae, 20-40 parts of millettia reticulata and 5-15 parts of ground beetle; The adjuvant drug is 5-15 parts of roasted licorice root.

3. The Chinese medicine composition for treating recurrence of ovarian cancer according to any one of claims 1 or 2, wherein the Chinese medicine composition is made of the following Chinese medicines in parts by weight: The main medicine includes one or more of 5-10 parts of bupleurum, 5-10 parts of scutellaria, 5-10 parts of cassia twig and 5-10 parts of dried ginger; The adjuvant drugs include 20-35 parts of peony root, 5-10 parts of siler, 20-35 parts of nightshade, 20-35 parts of white safflower, 40-60 parts of oldenlandia diffusa and 40-60 parts of barbata; The adjuvants include 5-8 parts of cinnamon bark, 10-15 parts of rhizoma corydalis, 10-15 parts of rhizoma pinelliae, 20-35 parts of reticulatae spatholobi and 5-10 parts of ground beetle; The adjuvant drug is 5-10 portions of roasted licorice root.

4. The Chinese medicine composition for treating ovarian cancer recurrence according to any one of claims 1 to 3, wherein the ovarian cancer recurrence includes biochemical recurrence and clinical recurrence; preferably, the ovarian cancer recurrence refers to biochemical recurrence.

5. A Chinese medicine preparation made from the Chinese medicine composition according to any one of claims 1 to 4, wherein the Chinese medicine preparation comprises pharmaceutically acceptable excipients required for the corresponding preparation.

6. The Chinese medicine preparation as claimed in claim 5, wherein the excipient is a pharmaceutical excipient that enhances the efficacy, reduces the toxicity and / or alleviates the side effects of the main drug.

7. The Chinese medicine preparation according to any one of claims 5 or 6, wherein the Chinese medicine preparation is one or more of a paste prescription, a pill, a pill, a decoction, a granule, a capsule, a powder and / or a tablet.

8. Use of the Chinese medicine composition according to any one of claims 1 to 4 or the Chinese medicine preparation according to any one of claims 5 to 7 in the preparation of a drug for treating recurrence of ovarian cancer.

9. The use of claim 8 in preparing a drug for treating ovarian cancer recurrence, wherein the ovarian cancer recurrence includes biochemical recurrence and clinical recurrence; preferably, the ovarian cancer recurrence refers to biochemical recurrence.

Citation Information

Patent Citations

  • Qiankun Yilidan pellet

    CN101284118A

  • Traditional Chinese medicine for treating ovarian cyst

    CN103893330A

  • A traditional Chinese medicine preparation used for treating ovarian cancer

    CN108653687A

  • Traditional Chinese medicinal preparation for strengthening and restoring effects and resisting cancer

    CN108785616A